Project Grant K99HL179261
- This Project Grant award, provided by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), supports research on how tissue elasticity and viscosity modulate the signaling between macrophages and fibroblasts in cardiac fibrosis. The $231,552 award, granted to the University of California, San Diego, will fund research to investigate the effects of mechanical stimuli on macrophage-fibroblast interactions and explore the role of a changing mechanical...
- This $298,368 Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports the development of a novel device for treating mitral valve regurgitation. The project aims to optimize the device design and procedure through bench testing, followed by acute in vivo studies to demonstrate the feasibility of the approach. The funding recipient, Link Medical LLC, has invented a catheter-based technology intended to restore proper mitral...
- The Project Grant award of $639,621 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research by the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University (CCLCM) to investigate mitochondrial signaling between cardiomyocytes and fibroblasts, and its role in cardiac fibrosis. The research aims to determine how cardiomyocyte-derived mitochondria mediate crosstalk with cardiac fibroblasts, which may underlie the...
- This $721,826 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to identify molecular mechanisms regulating alveolar matrix fibroblast function and their role in supporting vascular capillary formation. The research is being conducted by Children's Hospital Medical Center in Cincinnati, Ohio to advance the understanding of alveolar septation and septal wall maturation, which is...
- This federal Project Grant award of $740,037, funded by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), supports research on the regulation of angiogenesis (blood vessel formation) by cardiac fibroblasts following myocardial infarction. The key objectives are to investigate the temporal and spatial expression of pro- and anti-angiogenic factors secreted by cardiac fibroblasts to support cardiac repair and increase vascular...
- This federal Project Grant award for $249,000 was provided by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to Children's Hospital Medical Center in Cincinnati, Ohio. The grant supports research on the role of the PITX2 transcription factor in regulating left-right asymmetry and its impact on the development of atrial fibrillation (AF), the most common sustained heart rhythm disorder affecting 5% of the U.S. population. The research aims to...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $811,885 in funding to the J. David Gladstone Institutes in California to conduct research on epigenomic mechanisms of cardiac fibrosis and heart failure. The project aims to investigate the role of the MEOX1 gene as a key transcriptional regulator of fibroblast activation, fibrosis, and heart failure pathogenesis. The research leverages novel genetic mouse...
- The federal Project Grant award of $117,525.00 from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) is funding research at Boston Children's Hospital to investigate cellular adaptation to perturbations in one-carbon metabolism. The research aims to characterize the role of the UFMylation pathway in maintaining cellular fitness during folate depletion, and explore signaling cascades that promote cellular fitness in response to one-carbon metabolism...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) will provide $3,008,247 to the University of California, San Diego (UC San Diego) to conduct research on the cell-type specific mechanisms underlying mitral valve prolapse (MVP), a common valvular heart disease. The award will support a multi-disciplinary research effort utilizing single-cell and single-nucleus RNA sequencing and ATAC-sequencing technologies to identify...
- This $834,249 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports a comparative study of clinical outcomes, patient experiences, and mechanistic insights between transcatheter and surgical treatment of degenerative mitral regurgitation (DMR). The study aims to provide long-term data on clinical effectiveness, safety, and patient-reported outcomes to inform treatment selection and guide patient care. It will also utilize...
This federal Project Grant award of $118,632 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research by Children's Hospital Medical Center in Cincinnati, Ohio to investigate the role of matrifibrocytes in the progression of myxomatous heart valve disease. The research aims to study how stress and collagen overproduction in Marfan syndrome mitral valves induces matrifibrocytes, leading to a compensatory fibrotic response mediated by focal adhesion kinase (FAK) activation. The award period runs from August 2025 to July 2027. This grant builds on the organization's expertise in pediatric medicine, cardiovascular research, and federal contract work with agencies like the CDC on vaccine safety assessments.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $118.6k | 8/6/25 |